{{Rsnum
|rsid=11937061
|Gene=FTLP9
|Chromosome=4
|position=77215780
|Orientation=plus
|GMAF=0.3315
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 40.7 | 46.0 | 13.3
| HCB | 48.9 | 41.6 | 9.5
| JPT | 58.4 | 36.3 | 5.3
| YRI | 45.6 | 40.8 | 13.6
| ASW | 49.1 | 45.6 | 5.3
| CHB | 48.9 | 41.6 | 9.5
| CHD | 45.0 | 47.7 | 7.3
| GIH | 28.7 | 52.5 | 18.8
| LWK | 33.6 | 50.0 | 16.4
| MEX | 48.3 | 44.8 | 6.9
| MKK | 57.7 | 37.2 | 5.1
| TSI | 37.3 | 53.9 | 8.8
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=22491018
|Trait=None
|Title=Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis.
|RiskAllele=
|Pval=2E-7
|OR=6.7000
|ORtxt=None
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}
{{on chip | NatGeo2}}